OstrowJDMulvaneyCAHansellJRRhodesRS. Sensitivity and reproducibility of chemical tests for fecal occult blood with an emphasis on false-positive reactions. Am J Dig Dis1973; 18: 930–40.
2.
JaffeRMKastenBYoungDSMaclowryJD. False-negative stool blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med1975; 83: 824–6.
3.
MorrisDWHansellJROstrowJDLeeC. Reliability of chemical tests for fecal occult blood in hospitalized patients. Am J Dig Dis1976; 21: 845–52.
4.
StroehleinJRFairbanksVGMcGillDBGoVLW. Hemoccult detection of fecal occult blood quantitated by radioassay. Am J Dig Dis1976; 21: 841–4.
5.
HerzogPHoltermullerKH. Oral Cimetidine does not cause false-positive test for blood in stool (letter). N Engl J Med1981; 305: 644–5.
6.
LiftonLJKreiserJ. False-positive stool occult blood tests caused by iron preparations: a controlled study and review of literature. Gastroenterology1982; 83: 860–3.
7.
NorfleetRGRhodesRASaviageK. False-positive “Hemoccult” reaction with cimetidine (letter). N Engl J Med1980; 302: 467.
8.
SchentagJJ. False-positive “Hemoccult” reaction with Cimetidine (letter). N Engl J Med1980; 303: 220.
9.
SudlowGSkillmanJJGoldmanP. Pitfalls of Hemoccult testing of gastric aspirates (letter). N Engl J Med1981; 304: 1608.
10.
LayneEAMellowMHLipmanTO. Insensitivity of guaiac slide tests for detection of blood in gastric juice. Ann Intern Med1981; 94: 774–6.
11.
LongPCWilentzKVSudlowGSkillmanJJ. Modification of the Hemoccult slide test for occult blood in gastric juice. Crit Care Med1982; 10: 692–3.
12.
HauserARQuigleyMLDrieverCW. In vitro effect of Cimetidine concentration and pH on guaiac-slide tests. Am J Hosp Pharm1983; 40: 626–9.
13.
PleuraDAJohnsonLF. Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Inern Med1985; 103: 173–7.
14.
Package insert. Gastroccult. Sunnyvale, CA: Smith Kline Diagnostics, Inc., 1983.
15.
Physician's desk reference for nonprescription drugs. Oradell, NJ: Medical Economics Company Inc., 1984: 674.
16.
ReynoldsJEF, ed. Martindale: the extra pharmacopoeia. London: The Pharmaceutical Press, 1982: 957,959.
17.
BusseWWSchoenwetterWF. Asthma from psyllium in laxative manufacture. Ann Intern Med1975; 83: 361–2.
18.
BerntonHS. The allergenicity of psyllium seed. Med Ann Dist Columbia1970; 39: 313–7.
19.
GrossR. Acute bronchospasm associated with inhalation of psyllium hydrophilic mucilloid. JAMA1979; 241: 1573–4.
20.
GassJMNortonWD. Cystoid macular edema and papilledema following cataract extraction. Arch Ophthalmol1966; 75: 646–61.
21.
MaumeneeAE. Further advances in the study of the macula. Arch Ophthalmol1967; 78: 151–65.
22.
HenkindP. Foreword to first international cystoid macular edema symposium. Surv Ophthalmol1984; 28 (suppl): 431–2.
23.
BirdAC. Retinal edema. Introduction to the first international cystoid macular edema symposium. Surv Ophthalmol1984; 28 (suppl): 433–6.
24.
Cunha-VazJGTravassosA. Breakdown on the blood-retinal barriers and cystoid macular edema. Surv Ophthalmol1984; 28 (suppl): 485–92.
25.
YannuzziLA. A perspective on the treatment of aphakic cystoid macular edema. Surv Ophthalmol1984; 28 (suppl): 540–53.
26.
JampolLMSandersDRKraffMC. Prophylaxis and therapy of aphakic cystoid macular edema. Surv Ophthalmol1984; 28 (suppl): 535–9.
27.
KleinRMYannuzziL. Cystoid macular edema in the first week after cataract extraction. Am J Ophthalmol1976; 81: 614–5.
28.
IrvineARBreskyRCrowderBMForsterRKHunterDMKulvinSM. Macular edema after cataract extraction. Ann Ophthalmol1971; 3: 1234–9.
29.
JaffeNS. Cataract surgery and its complications. 3rd ed. St. Louis: C.V. Mosby Company, 1981: 357–73.
30.
YannuzziLALandauANTurtzAI. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology1981; 88: 947–54.
31.
JampolLM. Pharmacologic therapy of aphakic cystoid macular edema: a review. Ophthalmology1982; 89: 891–7.
32.
SearsML. Aphakic cystoid macular edema. The pharmacology of ocular trauma. Surv Ophthalmol1984; 28 (suppl): 525–34.
33.
MiyakeK. Indomethacin in the treatment of postoperative cystoid macular edema. Surv Ophthalmol1984; 28 (suppl): 554–68.
34.
JampolLM. Pharmacologic therapy of aphakic and pseudoaphakic cystoid macular edema. Ophthalmology1985; 92: 807–10.
ConquetPHPlazonnetJLedouarecJC. Arachidonic acidinduced elevation of intraocular pressure and anti-inflammatory agents. Invest Ophthalmol Vis Sci1975; 14: 772–5.
37.
SandersDRGoldstickBKraffCHutchinsRBersteinMSEvansMA. Aqueous penetration of oral and topical indomethacin in humans. Arch Ophthalmol1983; 101: 1614–6.
38.
YannuzziLAKleinRMWallynRHCohenNKatzI. Ineffectiveness of indomethacin in the treatment of chronic cystoid macular adema. Am J Ophthalmol1977; 84: 517–9.
39.
SholitonDBReinhartWJFrankKE. Indomethacin as a means of preventing cystoid macular edema following intracapsular cataract extraction. Am Intraocular Implant Soc J1979; 5: 137–40.
40.
KleinRMKatzinHMYannuzziLA. The effect of indomethacin pretreatment on aphakic cystoid macular edema. Am J Ophthalmol1979; 87: 487–9.
41.
MiyakeKSakamuraSMiuraH. Long-term follow-up study on prevention of aphakic cystoid macular edema by topical indomethacin. Br J Ophthalmol1980; 64: 324–8.
42.
MiyakeKMiyakeYMaekuboKAsakuraMManabeR. Incidence of cystoid macular edema after retinal detachment surgery and the use of topical indomethacin. Am J Ophthalmol1983; 95: 451–6.
43.
KraffMCSandersDRJampolLMPeymanGALiebermanHL. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology1982; 89: 885–90.
MannucciPMCancianiMTRotaLDonovanBS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand's disease. Br J Haematol1981; 47: 283–93.
46.
SweeneyJDCrosbyPMcCannSRTemperleyIJ. Clinical experience with desamino-8-D-ARG-vasopressin (DDAVP) in patients with factor VIII deficiency. Ir J Med Sci1981; 150: 236–9.
47.
NilssonIMMikaelssonMVilhardtHWalterH. DDAVP factor VIII concentrate and its properties in vivo and in vitro. Thromb Res1979; 15: 263–71.
48.
MarwickC. New ways to boost factor VIII in hemophilia: DDAVP for mild hemophilia A, von Willebrand's disease. JAMA1983; 249: 3278–9.
49.
LudlamCAPeakeIRAllenNDaviesBLFurlongRABloomAL. Factor VIII and fibrionolytic response to desamino-8-Darginine vasopressin in normal subjects and dissociate response in some patients with hemophilia and von Willebrand's disease. Br J Haematol1980; 45: 499–511.
50.
ProwseCVSasGGraderAMACortJHCashJD. Specificity in the factor VIII response to vasopressin infusion in man. Br J Haematol1979; 41: 437–47.
51.
DewaldDLBriggsBSmithRE. Intranasal administration of DDAVP to hemophiliacs. Thromb Res1980; 18: 617–22.
52.
SiglerJW. Parenteral gold in the treatment of rheumatoid arthritis. Am J Med1983; 75 (suppl 6A): 59–62.
53.
Drugs for rheumatoid arthritis. Med Lett Drugs Ther1985; 27: 25–8.
54.
KlinefelterHF. Reinstitution of gold therapy in rheumatoid arthritis after mucocutaneous reactions. J Rheumatol1975; 2: 21–7.
KayAGL. Myelotoxicity of gold. Br J Med1976; 2: 1266–8.
57.
JaffeIA. Penicillamine: an anti-rheumatoid drug. Am J Med1983; 75 (suppl 6A): 63–8.
58.
KeanWFDwoshILAnastassiadesTPFordPMKellyHG. The toxicity pattern of D-penicillamine therapy. Arthritis Rheum1980; 23: 158–64.
59.
StevenMAHunterJAMurdochRMCapellHA. Does the order of second-line treatment in rheumatoid arthritis matter?Br Med J1981; 284: 79–81.
60.
SteinHBRuedyJAtkinsCJOfferRC. Penicillamine compared to previous chrysotherapy in rheumatoid arthritis. J Rheumatol1983; 10: 319–22.
61.
SmithPJSwinburnWRSwinsonDRStewartIM. Influence of previous gold toxicity on subsequent development of penicillamine toxicity. Br Med J1982; 285: 595–6.
62.
HallaJTCassadyJHardinJG. Sequential gold and penicillamine therapy in rheumatoid arthritis. Am J Med1982; 72: 423–6.
63.
DoddMJGriffithsIDThompsonM. Adverse Reactions to D-penicillamine after gold toxicity. Br Med J1980; 2: 1498–1500.
64.
TsangIKPattersonCASteinHBRobinsonHSFordDK. D-penicillamine in the treatment of rheumatoid arthritis. Arthritis Rheum1977; 20: 666–70.
65.
KeanWFLockCJLHoward-LockHEBuchananWW. Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. Arthritis Rheum1982; 25: 917–22.
66.
Multicenter Trial Group. Absence of toxic or therapeutic interaction between penicillamine and previously administered gold in a trial of penicillamine in rheumatic disease. Postgrad Med J1974; 50: 77–8.
67.
WebleyMCoomesE. An assessment of penicillamine therapy in rheumatoid arthritis and the influence of previous gold therapy. J Rheumatol1979; 6: 20–4.
68.
DayATGoldingJR. Hazards of penicillamine therapy in the treatment of rheumatoid arthritis. Postgrad Med J1974; 50: 71–3.
69.
DippyJE. Penicillamine in rheumatoid arthritis—a 2 year retrospective study in 70 patients. Br J Clin Pract1977; 31: 5–11.
70.
BillingsleyLStevensM. Penicillamine proteinuria: a sequel to gold nephropathy (abstract). Arthritis Rheum1979; 22: 594.
71.
HyllandRCutlerJDooleyEBoleG. D-penicillamine toxicity, its relationship to antecedant gold salt toxicity (abstract). Arthritis Rheum1980; 23: 693.
72.
KeanWFLockCJL. Penicillamine does not chelate gold (editorial). J Rheumatol1983; 10: 9.
73.
GoldbergIJLLawtonKReddingJRFrancoisPEPhullJ. Effect of penicillamine on blood levels and urinary excretions of gold. Ann Clin Biochem1983; 20: 220.
74.
WooleyPHGriffinJPanayiGSBatchelorJRWelshKIGobsonTJ. HLA-DR antigens and toxic reactions to sodium aurothiomalate and d-penicillamine in patients with rheumatoid arthritis. N Engl J Med1980; 303: 300–2.
75.
DayATGoldingJR. Reaction to D-penicillamine in rheumatic arthritis (letter). Br Med J1973; 3: 593.
76.
BisnoALDismukesWEDurackDTTreatment of infective endocarditis due to viridans streptococci. Circulation1981; 63: 730–3A.
77.
WalterWREmilioGRJosephGE. Treatment of penicillin-sensitive streptococcal infective endocarditis. Mayo Clin Proc1982; 57: 95–100.
78.
ParrilloJEBorstGCMazurMHEndocarditis due to viridans streptococci during oral penicillin chemoprophylaxis. N Engl J Med1979; 300: 296–300.
DupervalRBillNJGeraciJEWashingtonJA. Bactericidal activity of combinations of penicillin or clindamycin with gentamicin or streptomycin against species of viridans streptococci. Antimicrob Agents Chemother1975; 8: 673–6.
81.
WatanakunakornCGlotzbeckerC. Synergism with aminoglycosides of penicillin, ampicillin and vancomycin against nonenterococcal group-D streptococci and viridans streptococci. J Med Microbiol1977; 10: 133–8.
82.
WolfeJCJohnsonWD. Penicillin-sensitive streptococcal endocarditis. Ann Intern Med1974; 81: 178–81.
83.
HorodniceanuTBuu-HoiADelbosFBiethG. High level aminoglycoside resistance in group A,B,G,D (Streptococcus bovis), and viridans streptococci. Antimicrob Agents Chemother1982; 21: 176–9.
84.
FarberBFEliopoulosGMWardJIRuoffKMoelleringRC. Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother1983; 24: 871–5.
85.
FisherJLeveneDL. The heterogeneity of Streptococcus viridans: therapeutic considerations in infective endocarditis. Can Med Assoc J1975; 112: 673–6.
86.
RahalJJ. Antibiotic combinations: the clinical relevance of synergy and antagonism. Medicine1978; 57: 179–95.
87.
NordenCW. Problems in determination of antibiotic synergism in vitro. Rev Infect Dis1982; 4: 276–81.
